FDA's "Act Now" Philosophy Has Drawbacks For Industry - CHPA Exec
This article was originally published in The Tan Sheet
Executive Summary
FDA's current speed in taking action sometimes sacrifices fair treatment of industry and can fail to allow for logistical realities, according to OTC stakeholders
You may also be interested in...
McNeil Expands Tylenol Recall As FDA Criticizes Firm's Response To AERs
McNeil Consumer Healthcare's reaction to signs of potentially contaminated packaging for OTC products including Tylenol raised FDA's ire and is now costing the firm an extensive product recall
McNeil Expands Tylenol Recall As FDA Criticizes Firm's Response To AERs
McNeil Consumer Healthcare's reaction to signs of potentially contaminated packaging for OTC products including Tylenol raised FDA's ire and is now costing the firm an extensive product recall
McNeil Expands Tylenol Recall As FDA Criticizes Firm's Response To AERs
McNeil Consumer Healthcare's reaction to signs of potentially contaminated packaging for OTC products including Tylenol raised FDA's ire and is now costing the firm an extensive product recall